Literature DB >> 11453948

Thyroid function in survivors of childhood acute lymphoblastic leukaemia: the significance of prophylactic cranial irradiation.

A Lando1, K Holm, K Nysom, U Feldt-Rasmussen, J H Petersen, J Müller.   

Abstract

OBJECTIVE: Focus on long-term side-effects after cancer therapy in childhood has become of the utmost importance. The hypothalamic-pituitary thyroid (HPT) axis is exposed to irradiation when some children are treated for acute lymphoblastic leukaemia (ALL) with prophylactic cranial irradiation (CIR). Whether this treatment causes hypofunction of the HPT axis remains controversial.
DESIGN: We measured plasma levels of total T3 (T3), total T4 (T4) and TSH before stimulation with TRH and plasma levels of TSH, 30 and 150 minutes after stimulation with TRH in 95 patients in first continuous remission of childhood ALL. PATIENTS: Patients diagnosed with ALL before the age of 15 years between 1970 and 1991 and who were in first continuous remission and off treatment for at least one year were studied. The children were aged between 0.5 and 14.8 years (median: 3.9) at diagnosis of ALL. Thyroid function was assessed between 1.2 and 18.3 years (median: 7.6) after completion of therapy. MEASUREMENTS: We measured T4 levels before, and compared TSH levels before and after, stimulation with TRH in patients who were treated with prophylactic CIR (15-24 Gy) (n = 38) (CIR group) with patients who were treated with chemotherapy only (n = 57) (non-CIR group).
RESULTS: We found that T3 and T4 levels were normal in all individuals (excluding the women who were on oral contraceptives). The median time from end of treatment to time at follow-up was 9.1 years in the non-CIR group vs. 4.2 years in the CIR group (P < 0.001), and the effect on follow-up time was significant (P = 0.04). It was estimated that just after irradiation, the TSH levels before and 30 and 150 minutes after TRH stimulation was 49% lower in the CIR group; however, after 4.0 years, TSH levels were not significantly different between the two groups. Although within normal limits, the T4 levels were significantly higher in the CIR group compared to the non-CIR group (P = 0.003). It was estimated that, just after the end of treatment, T4 was 19.9% higher in the CIR group. However, in the CIR group, the T4 level decreased significantly over time with -1.5% per year (P = 0.025), while the difference in the non-CIR group was not significant. There was no correlation between T4 and TSH levels and sex, age at diagnosis, age at the end of treatment or age at follow-up.
CONCLUSIONS: We conclude that, in our cohort of survivors of childhood ALL, prophylactic cranial irradiation of the central nervous system did not have an adverse effect on hypothalamo-pituitary-thyroid function within a median follow-up time of 8 years.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453948     DOI: 10.1046/j.1365-2265.2001.01292.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

Review 1.  Interactions between hypothalamic pituitary thyroid axis and other pituitary dysfunctions.

Authors:  Ulla Feldt-Rasmussen; Marianne Klose; Salvatore Benvenga
Journal:  Endocrine       Date:  2018-09-06       Impact factor: 3.633

Review 2.  Hypopituitarism as a consequence of brain tumours and radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study.

Authors:  Claire Oudin; Pascal Auquier; Yves Bertrand; Philippe Chastagner; Justyna Kanold; Maryline Poirée; Sandrine Thouvenin; Stephane Ducassou; Dominique Plantaz; Marie-Dominique Tabone; Jean-Hugues Dalle; Virginie Gandemer; Patrick Lutz; Anne Sirvent; Virginie Villes; Vincent Barlogis; André Baruchel; Guy Leverger; Julie Berbis; Gérard Michel
Journal:  Haematologica       Date:  2016-03-11       Impact factor: 9.941

Review 4.  Hypopituitarism following radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.

Authors:  Eric J Chow; Debra L Friedman; Marilyn Stovall; Yutaka Yasui; John A Whitton; Leslie L Robison; Charles A Sklar
Journal:  Pediatr Blood Cancer       Date:  2009-09       Impact factor: 3.167

6.  Late immune recovery in children treated for malignant diseases.

Authors:  Gabor T Kovacs; Olga Barany; Barbara Schlick; Monika Csoka; Judit Gado; Andrea Ponyi; Judit Müller; Julia Nemeth; Peter Hauser; Daniel J Erdelyi
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

7.  Endocrinological and cardiological late effects among survivors of childhood acute lymphoblastic leukemia.

Authors:  Pakize Karakaya; Sebnem Yılmaz; Ozlem Tüfekçi; Mustafa Kır; Ece Böber; Gülersu Irken; Hale Oren
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831

Review 8.  Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors.

Authors:  Cecilia Follin; Eva Marie Erfurth
Journal:  Curr Treat Options Oncol       Date:  2016-09

Review 9.  Less known aspects of central hypothyroidism: Part 1 - Acquired etiologies.

Authors:  Salvatore Benvenga; Marianne Klose; Roberto Vita; Ulla Feldt-Rasmussen
Journal:  J Clin Transl Endocrinol       Date:  2018-09-26

10.  Declining free thyroxine levels over time in irradiated childhood brain tumor survivors.

Authors:  Laura van Iersel; Sarah C Clement; Antoinette Y N Schouten-van Meeteren; Annemieke M Boot; Hedi L Claahsen-van der Grinten; Bernd Granzen; K Sen Han; Geert O Janssens; Erna M Michiels; A S Paul van Trotsenburg; W Peter Vandertop; Dannis G van Vuurden; Hubert N Caron; Leontien C M Kremer; Hanneke M van Santen
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.